2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Carcinoma, Hepatocellular
29
Neoplasms
18
Neoplasm Metastasis
14
Melanoma
14
Stomach Neoplasms
13
Esophageal Neoplasms
13
Colorectal Neoplasms
12
Nasopharyngeal Carcinoma
11
Esophageal Squamous Cell Carcinoma
10
Triple Negative Breast Neoplasms
9
Head and Neck Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Breast Neoplasms
8
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Lung Neoplasms
7
Carcinoma, Renal Cell
7
Biliary Tract Neoplasms
7
Small Cell Lung Carcinoma
6
Colonic Neoplasms
5
Cholangiocarcinoma
5
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Liver Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Surveys and Questionnaires
23
Radiotherapy
22
Letrozole
22
Doxorubicin
21
Megestrol Acetate
20
olaparib
19
lenvatinib
19
Taxes
17
Specimen Handling
17
Docetaxel
17
Nivolumab
16
Magnetic Resonance Spectroscopy
16
dostarlimab
15
Metformin
15
Blood Specimen Collection
14
Observation
13
Gemcitabine
13
Biopsy
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
temsirolimus
10
abemaciclib
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled